Insulet Corporation (PODD)
Insulet makes the Omnipod, a clever, tubeless wearable device that automatically delivers insulin to people living with diabetes.
Is Insulet Corporation a good stock for a UK beginner?
The honest version: Insulet makes the Omnipod, a clever, tubeless wearable device that automatically delivers insulin to people living with diabetes.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Becoming the standard of care for insulin delivery globally
Technological disruption making pods obsolete
What does Insulet Corporation do?
Insulet simplifies life for people with diabetes by replacing traditional, bulky insulin pumps with a small, waterproof pod that sticks to the skin and is controlled by a smartphone. Those disposable pods, which need replacing every few days, are what pay the bills and keep customers coming back. What really matters here is whether they can keep expanding their user base while fending off competition from other medical tech giants.
On our factor screen it looks strongest on growth and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 34% over the year
- !High P/E of 39 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 23%)
- Growth screens high (89/100)
- High profit margins on each pod sold
- Strong, recurring revenue from repeat pod purchases
- Innovative technology that improves quality of life for patients
- Momentum screens low (20/100)
- Income screens low (16/100)
- Heavy reliance on a single core product line
- Intense competition from established medical device companies
- Potential changes to healthcare reimbursement policies
What do Insulet Corporation's numbers mean?
How much money does Insulet Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Insulet Corporation pay a dividend?
No - Insulet Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Insulet Corporation report earnings, and how did recent quarters go?
Insulet Corporation is next scheduled to report on about 2026-08-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-06 | $1.19 | $1.42 | Beat +19% |
| 2026-02-18 | $1.46 | $1.55 | Beat +6% |
| 2025-11-06 | $1.15 | $1.24 | Beat +8% |
| 2025-08-07 | $0.92 | $1.17 | Beat +27% |
| 2025-05-08 | $0.79 | $1.02 | Beat +30% |
| 2025-02-20 | $1.02 | $1.15 | Beat +13% |
Across the last 6 quarters here, Insulet Corporation came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Insulet Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Insulet Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins on each pod sold
- Strong, recurring revenue from repeat pod purchases
- Innovative technology that improves quality of life for patients
- No dividend payments for shareholders
- High valuation compared to traditional companies
- Significant share price volatility over the last year
- Heavy reliance on a single core product line
- Intense competition from established medical device companies
- Potential changes to healthcare reimbursement policies
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in revenue growth rates
- A major safety recall of the pod devices
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.